Skip to content
Monument Therapeutics Logo Monument Therapeutics Logo
  • About
    • Leadership Team
    • Advisory Board
  • Pipeline
  • Publications
  • News
  • Contact
  • Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

By matt.poulter|2022-08-02T18:51:31+00:00August 2nd, 2022|

Read More
  • Monument Therapeutics
    Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation

By matt.poulter|2022-06-13T08:39:19+00:00June 13th, 2022|

Read More
  • Monument is attending BIO
    We are attending the BIO Conference: join us at two exciting sessions

We are attending the BIO Conference: join us at two exciting sessions

By matt.poulter|2022-06-07T09:06:30+00:00June 7th, 2022|

Read More
  • Monument Therapeutics JB
    Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)

Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)

By matt.poulter|2022-05-02T10:56:58+00:00May 2nd, 2022|

Read More
  • In Vivo Rising Leader
    Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!

Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!

By matt.poulter|2022-04-26T18:22:28+00:00April 26th, 2022|

Read More
  • Jenny Barnett Talk Post
    Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

By matt.poulter|2022-04-11T09:02:21+00:00April 11th, 2022|

Read More
  • monument new image
    Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference

By matt.poulter|2022-03-15T07:10:28+00:00March 15th, 2022|

Read More
  • monument new image
    Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference

By matt.poulter|2022-03-15T07:07:08+00:00March 15th, 2022|

Read More
  • Monument Therapeutics
    Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic

By matt.poulter|2021-12-14T14:51:25+00:00December 14th, 2021|

Read More
  • Monument Therapeutics
    Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study

By matt.poulter|2021-09-21T16:59:36+00:00September 21st, 2021|

Read More
12Next
© Copyright    |   info@monumenttx.com    |   Privacy Policy and Terms of Use   |   Website made by genapse
This website uses cookies and third party services. Ok